Effect of different direct-acting antivirals on the clinical outcome of genotype 1b chronic hepatitis C and compensated hepatitis C cirrhosis

Hou YiHui; Liu TengFei; Zhao XiaoQing; Zhang LiaoYun

doi:10.3969/j.issn.1001-5256.2020.01.019

Volume 36 Issue 1

Jan. 2020

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2020 > 36(1): 84-87

PDF( 2106 KB)

Effect of different direct-acting antivirals on the clinical outcome of genotype 1b chronic hepatitis C and compensated hepatitis C cirrhosis

DOI: 10.3969/j.issn.1001-5256.2020.01.019

Shanxi Medical University

Received Date: 2019-08-18
Published Date: 2020-01-20

Abstract

Abstract

Objective To investigate the effect of different direct-acting antivirals(DAAs) on the clinical outcome of genotype 1 b chronic hepatitis C(CHC) and compensated liver cirrhosis(CLC). Methods A total of 115 patients with genotype 1 b CHC and CLC who were treated in Department of Infectious Diseases in The First Hospital of Shanxi Medical University from January to December,2018 were enrolled as subjects,among whom there were 91 patients with CHC and 24 patients with CLC. All patients were given antiviral therapy with DAAs according to their conditions. Among the patients with CHC,28 were treated with sofosbuvir and velpatasvir(SOF + VEL),21 were treated with elbasvir and grazoprevir tablets(EBR + GZR),16 were treated with ombitasvir and dasabuvir(OBV + DSV),13 were treated with sofosbuvir and daclatasvir(SOF + DCV),and 13 were treated with sofosbuvir and ribavirin(SOF + RBV); among the 24 patients with CLC,15 were treated with sofosbuvir and velpatasvir(SOF + VEL),4 were treated with elbasvir and grazoprevir tablets(EBR + GZR),and5 were treated with sofosbuvir and daclatasvir(SOF + DCV). The two groups were compared in terms of normalization rate of liver function and virologic response rate,and adverse drug reactions were observed. The t-test was used for comparison of continuous data between groups,and the chi-square test was used for comparison of categorical data between groups. Results Of all patients,90. 4% achieved super-rapid virologic response at 1 week of treatment,98. 2% achieved rapid virologic response at week 4 of treatment,100% achieved complete early virologic response at week 12 of treatment,and 100% achieved sustained virologic response at week 12 after the end of treatment.There was no significant difference in HCV RNA seroconversion rate between the patients receiving different antiviral treatment regimens at weeks 1 and 4 of treatment(χ2= 2. 83 and 0. 07,P > 0. 05). All antiviral treatment regimens significantly improved the liver function of patients,and there was no significant difference in clinical outcome between different groups(χ2= 0. 83 and 1. 23,P > 0. 05). Both groups had no significant increase or reduction in renal function parameters after 12 weeks of the treatment with DAAs(t = 1. 32 and 0. 56,P >0. 05). There was a low incidence rate of adverse events,with two cases of nausea(1. 74%) and one case each of dizziness,palpitation,rash,and hemolysis(0. 87%). Conclusion In patients with genotype 1 b disease,DAA antiviral regimens selected based on their conditions can achieve good virologic response rate,with significant improvement in liver function and a low incidence rate of adverse events.
- chronic hepatitis C,
- antiviral agents,
- treatment outcome,
- sustained virologic response

FullText(HTML)

References(14)

References

[1] HOU F,QI HY,YIN CH. Progress in drug treatment of chronic hepatitis C[J]. Chin J Med,2017,52(4):1-3.(in Chinese)侯斐，齐海宇，阴赪宏．慢性丙型肝炎的药物治疗进展[J]．中国医刊，2017,52(4):1-3.

[2] Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. The guideline of prevention and treatment for hepatitis C:A 2015 update[J]. J Clin Hepatol,2015,31(12):1961-1979.(in Chinese)中华医学会肝病学分会，中华医学会感染病学分会．丙型肝炎防治指南(2015年更新版)[J]．临床肝胆病杂志，2015,31(12):1961-1979.

[3] KOHLI A,ALSHATI A,GEORGIE F,et al. Direct-acting antivirals for the treatment of chronic hepatitis C in patients with chronic kidney disease[J]. Therap Adv Gastroenterol,2016,9(6):887-897.

[4] WANG YB,XIE W. Chronic hepatitis C treatment:Hot spots,difficulties and problems that need to be solved[J]. Chin Clin Dr,2019,47(3):253-254.(in Chinese)王艳斌，谢雯．慢性丙型肝炎治疗:热点、难点及亟须解决的问题[J]．中国临床医生杂志，2019,47(3):253-254.

[5] HONER Z,MAASOUMY B,MARRA F,et al. Drug-drug interactions with novel all oral interferon-free antiviral agents in a large real-world cohort[J]. Clin Infect Dis,2016,62(5):561-567.

[6] CHEN JH,ZENG Z,ZHANG XX. Efficacy and safety of combined directly acting antivirals for treatment of Chinese chronic hepatitis C patients in a real-world setting[J]. World J Gastroenterol,2017,23(22):4072-4079.

[7] ZHUANG LW,JI SB,ZHANG Y,et al. Efficacy and safety of Sofosbuvir combined with Velpatasvir in treatment of chronic hepatitis C and hepatitis C related liver cirrhosis patients with genotype 1~6:A Meta-analysis[J/CD]. Chin J Liver Dis:Electr Version,2019,11(2):30-36.(in Chinese)庄立伟，纪世博，张雨，等．Sofosbuvir联合Velpatasvir治疗1~6基因型慢性丙型肝炎和丙型肝炎肝硬化患者疗效及安全性Meta分析[J/CD]．中国肝脏病杂志:电子版，2019,11(2):30-36.

[8] WANG JJ,WANG YB. Progress in direct antiviral drugs for hepatitis C virus[J]. Chin Clin Dr,2019,47(3):258-261.(in Chinese)王京京，王艳斌．丙型病毒性肝炎直接抗病毒药物研究进展[J]．中国临床医生杂志，2019,47(3):258-261.

[9] YIN YX,MENG ZQ,LI XG,et al. Clinical effect of direct-acting antiviral agents for hepatitis C[J]. Chin Hepatol,2018,23(9):772-774.(in Chinese)尹艳霞，孟子强，李晓光．直接抗病毒药物治疗慢性丙型肝炎的临床疗效观察[J]．肝脏，2018,23(9):772-774.

[10] AN ZY,SHENG QJ,DING Y,et al. Early efficacy and safety of direct-acting antivirals agents for the treatment of cirrhotic patients with hepatitis C[J]. Infect Dis Info,2016,29(2):81-84,96.(in Chinese)安子英，盛秋菊，丁洋，等．直接抗病毒药物治疗丙型肝炎肝硬化早期抗病毒疗效及安全性临床实践研究[J]．传染病信息，2016,29(2):81-84,96.

[11] JI F,WANG W,DANG S,et al. Outcomes after sofobuvircontaining regimes for hepatitis C virus in patients with decompensated cirrhosis:A real-world study[J]. Infect Agent Cancer,2017,12:48.

[12] JI D,CHEN GF,WANG C,et al. Twelve-week ribavirinfree direct-acting antivirals for treatment-experienced Chinese with HCV genotype 1b infection including cirrhotic patients[J]. Hepatol Int,2016,10(5):798-798.

[13] YANG Y,DANG SS. Safety of direct antiviral agents for treatment of hepatitis C virus infection[J]. World Chin J Dig,2017,25(8):659-669.(in Chinese)杨颖，党双锁．丙型肝炎直接抗病毒药物安全性应用进展[J]．世界华人消化杂志，2017,25(8):659-669.

[14] BUNNELL KL,VIBHAKAR S,GLOWACKI RC,et al. Nephrotoxicity associated with concomitant use of ledipasvir-sofosbuvir and tenofovir in a patient with hepatitis C virus and human immunodeficiency virus coinfection[J]. Pharmacotherapy,2016,36(9):e148-e153.

Relative Articles

[1]	Zhao JinHua, Li JunFeng, Mao XiaoRong. Effect of T-lymphocyte phenotype on immune status in chronic hepatitis B virus infection and its application value[J]. Journal of Clinical Hepatology, 2020, 36(5): 1019-1023. doi: 10.3969/j.issn.1001-5256.2020.05.014
[2]	Chen Bin, Zhang Tao, Zhu WenFang, Peng Jie, Zhang QianQian, Li YunFang, Ding XiuLi. Effect of the warming and heat-clearing method on the percentage of regulatory T lymphocytes/T helper 17 cells in rats with acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2018, 34(12): 2642-2647. doi: 10.3969/j.issn.1001-5256.2018.12.026
[3]	Gao WeiHua, Ge KuanXue, Xiang XiaoXing. Association of Th17 cells, regulatory T cells, and their imbalance with nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2018, 34(6): 1347-1350. doi: 10.3969/j.issn.1001-5256.2018.06.046
[4]	Wang Yan, Huang YouYing, Ma Yan, Guo Feng, Wang XiaoBo, Wang XiaoZhong. Expression features of follicular helper T cells in peripheral blood in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2018, 34(1): 58-62. doi: 10.3969/j.issn.1001-5256.2018.01.012
[5]	Ge KuanXue, Gao WeiHua, Xiang XiaoXing. Association of regulatory T cells, T helper 17 cells, and change in their balance with autoimmune hepatitis[J]. Journal of Clinical Hepatology, 2018, 34(7): 1573-1576. doi: 10.3969/j.issn.1001-5256.2018.07.045
[6]	Li JianYun, Tu ChuanQing, He De, Wang DianWen, Huang Can, Zhang XuYan, Feng Chun. Clinical significance of measurement of T lymphocyte subsets before splenectomy in patients with primary immune thrombocytopenia[J]. Journal of Clinical Hepatology, 2017, 33(1): 150-154. doi: 10.3969/j.issn.1001-5256.2017.01.033
[7]	He JunNan, Zhao ShouSong. Research advances in association between regulatory T cells and hepatitis B virus infection[J]. Journal of Clinical Hepatology, 2016, 32(2): 361-365. doi: 10.3969/j.issn.1001-5256.2016.02.036
[8]	Zhang FeiFei, Chen Hui, Lyu Jun. Role of T-helper cell 17 in the development and progression of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2016, 32(8): 1626-1629. doi: 10.3969/j.issn.1001-5256.2016.08.046
[9]	Ji LongShan, Sun XueHua, Zhou ZhenHua, Zhang Xin, Gao YaTing, Gao YueQiu, Li Man. Role of follicular helper T cells in development and progression of liver diseases[J]. Journal of Clinical Hepatology, 2016, 32(6): 1230-1234. doi: 10.3969/j.issn.1001-5256.2016.06.050
[10]	Zhou Yan, Jing Xiang, Zhu ZhengYan. Roles of regulatory T cells and T-helper cells in hepatitis B virus-related liver diseases[J]. Journal of Clinical Hepatology, 2016, 32(10): 1994-1997. doi: 10.3969/j.issn.1001-5256.2016.10.040
[11]	Li CaiDong, Chen XiLian, Duan ZhengJun, Liu XueMei, Wu Bin. Determination of proportions of T cell subsets and levels of interleukin-15 and interleukin-16 in peripheral blood of patients with chronic hepatitis B virus infection and correlation between them[J]. Journal of Clinical Hepatology, 2015, 31(11): 1857-1861. doi: 10.3969/j.issn.1001-5256.2015.11.021
[12]	Shi GuangYing, Ma XiaoYuan, Xie JingDong. Changes in T lymphocyte subsets and cytokines in peripheral blood of patients with primary biliary cirrhosis after treatment with different doses of ursodeoxycholic acid[J]. Journal of Clinical Hepatology, 2015, 31(9): 1447-1451. doi: 10.3969/j.issn.1001-5256.2015.09.020
[13]	Li CaiDong, Chen XiLian, Tian PengFei, Li HuiJun, Wu Bin. Correlation analysis of percentages of T lymphocyte subsets and CD4~+CD25~+ regulatory T cells and HBV DNA level in peripheral blood of chronic hepatitis B patients[J]. Journal of Clinical Hepatology, 2015, 31(4): 541-545. doi: 10.3969/j.issn.1001-5256.2015.04.016
[14]	Wang Yu, Ma ZhiYuan, Guo YongHong, He Yu, Zhang Ying, Xie YuMei, Ma Li, Zhou Yun, Jia ZhanSheng. Investigation of CD4+CXCR5+ follicular helper T cell frequency and expression of related functional molecules in peripheral blood of hepatitis C virus patients[J]. Journal of Clinical Hepatology, 2013, 29(5): 379-382.
[15]	Ding QiaoYun, Yu HaiYing, Sun WeiWei, Pan Jian, Cao XingGuo, Wang Lei. The changes of peripheral blood T-lymphocyte subsets in pediatric severe hepatitis[J]. Journal of Clinical Hepatology, 2011, 27(7): 729-730.

Supplements(0)

Cited By

Cited by

Periodical cited type(8)

1.	蒋丽莎，马洪升. 日归手术——中国日间手术的升华. 华西医学. 2022(02): 161-164 .
2.	雷甜甜，梁鹏，马洪升，蒋丽莎. 四川大学华西医院日归手术管理实践. 广东医学. 2022(10): 1222-1228 .
3.	方宁波，陈伟力. 腹腔镜胆囊切除术日间手术围术期指标观察及患者延迟出院原因分析. 江西医药. 2022(10): 1524-1527 .
4.	刘力玮，郑亚民，刘东斌，王悦华，刘家峰，梁阔，江华，高崇崇，于志浩，徐大华. 日间腹腔镜胆囊切除术的可行性分析. 腹腔镜外科杂志. 2021(05): 359-362 .
5.	杨奕夫，黎柏峰，肖艳. 日间腹腔镜胆囊切除术质量控制的研究进展. 腹腔镜外科杂志. 2020(10): 796-798+800 .
6.	李航，赵礼金. 老年患者腹腔镜胆囊切除日间手术的安全性分析. 中国普通外科杂志. 2019(08): 1012-1017 .
7.	石鑫，秦琦瑜，刘维丽，胥静，王威. “三镜”联合治疗胆囊结石合并肝外胆管结石手术效果及安全性研究. 临床军医杂志. 2018(06): 710-712 .
8.	张少成，张亚辉，徐小梦. 年龄因素对上胆道疾病患者行腹腔镜胆囊切除术安全性的影响. 深圳中西医结合杂志. 2018(06): 184-186 .

Other cited types(1)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (1432) PDF downloads(241)

Effect of different direct-acting antivirals on the clinical outcome of genotype 1b chronic hepatitis C and compensated hepatitis C cirrhosis

DOI: 10.3969/j.issn.1001-5256.2020.01.019